# Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

> **NCT02437019** · — · APPROVED_FOR_MARKETING · sponsor: **Janssen-Cilag Farmaceutica Ltda.**

## Conditions studied

- B-cell Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** PCI-32765 (Ibrutinib)

## Key facts

- **NCT ID:** NCT02437019
- **Lead sponsor:** Janssen-Cilag Farmaceutica Ltda.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2017-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02437019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02437019, "Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02437019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*